Xetra
17.11.25 | 13:50
144,30 Euro
-0,24 % -0,35
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 144,35 | 145,50 | 14:57 | |
| 144,35 | 145,70 | 14:57 |
► 17.11.: | | | | | |
15:00 |
16:00 |
17:00 |
17:30
► 14.11.: | | | | | | | | |
► Aktueller BIOGEN Börsenkurs + Xetra-Orderbuch
► 14.11.: | | | | | | | | |
► Aktueller BIOGEN Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 147,00 | 1.900 | |||
| 146,95 | 33 | |||
| 146,90 | 375 | |||
| 146,65 | 2 | |||
| 146,55 | 412 | |||
| 146,50 | 252 | |||
| 146,35 | 34 | |||
| 146,25 | 50 | |||
| 146,20 | 70 | |||
| 145,70 | 137 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/idp.htm [/URL] | ||||
| 50 | 144,65 | |||
| 59 | 144,60 | |||
| 140 | 144,25 | |||
| 70 | 144,20 | |||
| 120 | 143,85 | |||
| 14 | 143,80 | |||
| 2 | 143,65 | |||
| 12 | 143,40 | |||
| 19 | 143,15 | |||
| 78 | 143,10 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 564 | 5,789 | 3.265 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 13:50:24 | 144,30 | 7 |
| 13:03:57 | 144,85 | 10 |
| 12:05:48 | 145,60 | 52 |
| 12:00:01 | 145,95 | 2 |
| 12:00:01 | 145,90 | 50 |
| 11:14:19 | 145,90 | 10 |
| 10:50:29 | 146,00 | 49 |
| 10:50:29 | 146,00 | 50 |
| 10:50:29 | 146,00 | 10 |
| 10:50:29 | 146,00 | 23 |
| 10:50:29 | 145,95 | 8 |
| 10:36:49 | 146,00 | 35 |
| 10:00:01 | 145,75 | 3 |
| 09:59:14 | 145,75 | 2 |
| 09:52:38 | 145,70 | 12 |
| 09:38:17 | 145,10 | 1 |
| 09:11:14 | 146,15 | 4 |
| 09:04:05 | 145,00 | 11 |
| 09:04:05 | 145,00 | 5 |
| 09:04:04 | 145,00 | 56 |
| Tagesumsatz Xetra | -0,35 -0,24 % | 400 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:07 | Biogen Completes Acquisition of Alcyone Therapeutics | 7 | FinSMEs | ||
| 13:46 | Biogen Inc.: Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments | 165 | GlobeNewswire (Europe) | - Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative... ► Artikel lesen | |
| 12:10 | Biogen Inc.: High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy | 176 | GlobeNewswire (Europe) | Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg... ► Artikel lesen | |
| Fr | Biogen completes acquisition of Alcyone Therapeutics | 6 | Investing.com | ||
| BIOGEN Aktie jetzt für 0€ handeln | |||||
| Fr | Biogen Inc.: Biogen Completes Acquisition of Alcyone Therapeutics | 357 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Nov. 14, 2025Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions... ► Artikel lesen |
1 2 3 4 5 Weiter >>
293 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 13:10 | Immatics Announces Third Quarter 2025 Financial Results and Business Update | GlobeNewswire (Europe) | Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will... ► Artikel lesen | |
| 14:10 | Krystal Biotech: Gentherapie-Pionier vor neuen Hochs? | sharedeals.de | Die Aktie von Krystal Biotech hat in den vergangenen Monaten stark an Dynamik gewonnen und notiert fast auf ihrem Allzeithoch aus 2024. Die Erwartungen an das Unternehmen bleiben hoch, doch mit dem... ► Artikel lesen | |
| 13:42 | Morning Market Movers: Zymeworks, WeShop, Taitron Components, Repare Therapeutics See Big Swings | AFX News | CANBERA (dpa-AFX) - At 7:15 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 13:38 | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Newsfile | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| 14:14 | Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs | ACCESS Newswire | ~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Ensysce Biosciences... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOGEN INC finden Sie auf Wallstreet Online.